Insights into Chronic Myeloid Leukemia (CML) Northwest
Perspectives of community physicians from the northwest of the US on the management of newly diagnosed and TKI-resistant/progressive CML
Northwest – December 11, 2020
Faculty Chair
Javier Pinilla, MD, PhD
Moffitt Cancer Center, Tampa, FL, US
REPORT SNAPSHOT
- A moderated virtual roundtable discussion focusing on treatment of CML was held on Friday, December 11, 2020
- Disease state and data presentations were developed in conjunction with a medical expert from Moffitt Cancer Center
- Insights on the following CML therapies were obtained: bosutinib, dasatinib, imatinib, nilotinib, omacetaxine, and ponatinib
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collected via audience response system questioning and in-depth moderated discussion
- The group of advisors comprised 12 community oncologists from California, Oregon, Wyoming, and Washington
